Navigation Links
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator
Date:7/14/2009

VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM). The data was disclosed as part of the preclinical characterization of the development candidate EVP-0962.

EVP-0962 is a proprietary small molecule that belongs to a new generation of potential Alzheimer drugs known as gamma-secretase modulators (GSMs). As a gamma-secretase modulator, EVP-0962 selectively inhibits the production of the toxic AB42 peptide without affecting the total amount of AB. As EVP-0962 does not affect other gamma secretase substrates required for normal function, such as Notch, it is predicted to slow the progression of Alzheimer's disease by reducing the disease-associated toxic AB42 species and to display an intrinsically superior safety profile compared to gamma secretase inhibitors (GSIs).

EVP-0962 selectively reduces the production of AB42 in multiple cell lines and in the brains of normal mice and rats after a single dose. It significantly reduces the production of AB42 in the brains of transgenic mice after two months of daily oral administration. In the same transgenic Alzheimer's disease model, mice developed deficits in the hippocampal memory task known as contextual fear conditioning. Chronic dosing with EVP-0962 reverses these deficits back to normal (wild type) levels. EVP-0962 also displays an excellent safety profile in a 14-day rat toxicology study, confirming suitability for clinical development.

"We are very excited about these findings since they represent to us the first demonstration with a bona fide GSM of functional improvement in an Alzheimer's disease model with concomitant lowering of AB42," said Kees Been, president & CEO of EnVivo. "We have also described the acute AB42 lowering effects of EVP-0962 in brains of non-transgenic as well as transgenic rodents. The fact that EVP-0962 also improves the cognitive deficits is very encouraging and confirms that EVP-0962 is an ideal molecule to test the AB-hypothesis in our upcoming human clinical trials."

Based on the success of these experiments, EnVivo has now entered preclinical development with EVP-0962 and expects to begin clinical trials in 2010.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
4. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
5. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
6. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
7. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
10. OncoGenex Pharmaceuticals Added to Russell Indexes
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that the ... provides capabilities for managing and processing genomic and health data at petabyte scale. ... collecting and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. ...
(Date:2/10/2016)... Vancouver, BC (PRWEB) , ... February 09, 2016 ... ... and design services and current winner of the Highest Overall Customer Rating ... certification in all of its business units across the USA, Canada, Mexico and ...
(Date:2/9/2016)... ... ... Date and time: March 1, 2016, 5:30 p.m. to ... of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The Baruch ... house for participants to learn about a new Master of Biomedical Science (MBS) ...
(Date:2/9/2016)... ... , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre has joined the firm ... new accounts and work closely with existing Tunnell clients throughout Europe to ensure their ... clients more than 15 years of experience in the pharmaceutical industry, a thorough knowledge ...
Breaking Biology Technology:
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):